Why Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 6.08%
As of Wednesday, September 09, Xtant Medical Holdings, Inc.’s XTNT share price has dipped by 6.08%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Xtant Medical Holdings, Inc. (XTNT)
Xtant Medical Holdings, Inc. XTNT
$0.37
0.00
-1.01%
September 24, 2026 3:45:20 PM
EST
Volume: 70,064
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
AMEX | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.
Commentary & Analysis
Why Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 7.92%
As of Tuesday, September 08, Xtant Medical Holdings, Inc.’s XTNT share price has surged by 7.92%, which has investors questioning if this is right time to sell.Michael Rose
Why Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 6.68%
As of Wednesday, September 02, Xtant Medical Holdings, Inc.’s XTNT share price has surged by 6.68%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 10.24%
As of Wednesday, September 02, Xtant Medical Holdings, Inc.’s XTNT share price has surged by 10.24%, which has investors questioning if this is right time to sell.Omar Beirat
Why Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 6.25%
As of Tuesday, September 01, Xtant Medical Holdings, Inc.’s XTNT share price has dipped by 6.25%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | XTNT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $52.6 | $367.8 | 15% |
|
| Shares Out (Mil) | 140.3 | 40.8 | 69% |
|
| Institutional Ownership | 51.6% | 82.8% | 36% |
|
| Float (Mil) | 54.2 | 35.5 | 49% |
|
| Beta | -0.15 | 0.85 | 4% |
|
| Avg Daily Volume (000s) | 301 | 310 | 49% |
|
| Price Change (52-week) |
(42.3%) | 65.6% | 21% |
|
| Growth | XTNT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 20.2% | 11.8% | 81% |
|
| Net Income (5yr) | 22.1% | (5.7%) | 76% |
|
| EPS (5yr) | 16.2% | 10.2% | 60 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 22.9% | (15.5%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 1 | 3 | |
| Current EPS | ($0.023) | ($0.080) | ($0.030) | |
| Month Ago EPS | ($0.020) | na | ($0.040) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.010) | ($0.080) | ($0.005) | |
| Year/Year Chg | (67.1%) | (366.7%) | (56.7%) | |
| Financials | XTNT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $110 | $119 | 27% |
|
| Net Income (TTM) (Mil) | ($11) | ($9) | 28% |
|
| EPS (TTM) | ($0.080) | ($0.400) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | $1 | ($3) | 33% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $1 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $23 | 28% |
|
| Enterprise Value (Q1) (Mil) | $61 | $376 | 17% |
|
| Valuation | XTNT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.29 | 2.72 | 33% |
|
| P/E | na | 25.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | XTNT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.4% | 58.5% | 72% |
|
| Net Margin | (10.2%) | (6.9%) | 21% |
|
| ROA | (12.2%) | (12.3%) | 24% |
|
| ROE | (25.2%) | (11.1%) | 21% |
|
| Liabilities to Assets | 49.8% | 46.6% | 42% |
|
| F-Score | 3 | 4 | 18% |
|
Xtant Medical Holdings, Inc. did not pass any screens on 9/23/2026.
